Vetoquinol is forecast to grow earnings and revenue by 3.9% and 3.3% per annum respectively. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be 8.7% in 3 years.
Key information
3.9%
Earnings growth rate
6.08%
EPS growth rate
Pharmaceuticals earnings growth
24.1%
Revenue growth rate
3.3%
Future return on equity
8.70%
Analyst coverage
Low
Last updated
22 May 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
DB:8JM - Analysts future estimates and past financials data (EUR Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
579
64
71
93
4
12/31/2027
551
59
64
87
4
12/31/2026
522
56
72
95
2
12/31/2025
526
57
51
72
N/A
9/30/2025
529
59
50
71
N/A
6/30/2025
532
60
49
71
N/A
3/31/2025
536
59
59
78
N/A
12/31/2024
539
59
68
86
N/A
9/30/2024
538
53
69
86
N/A
6/30/2024
537
47
70
86
N/A
3/31/2024
533
51
70
88
N/A
12/31/2023
529
56
70
89
N/A
9/30/2023
527
57
76
98
N/A
6/30/2023
525
59
83
106
N/A
3/31/2023
533
53
61
84
N/A
12/31/2022
540
48
40
63
N/A
9/30/2022
538
48
29
54
N/A
6/30/2022
537
48
17
46
N/A
3/31/2022
529
55
37
68
N/A
12/31/2021
521
63
57
90
N/A
9/30/2021
504
52
-1
91
N/A
6/30/2021
487
40
-59
93
N/A
3/31/2021
457
30
-56
93
N/A
12/31/2020
427
19
-53
92
N/A
9/30/2020
418
25
5
85
N/A
6/30/2020
408
31
64
78
N/A
3/31/2020
402
30
51
65
N/A
12/31/2019
396
29
38
52
N/A
9/30/2019
385
31
N/A
43
N/A
6/30/2019
374
33
N/A
35
N/A
3/31/2019
371
35
N/A
36
N/A
12/31/2018
368
36
N/A
38
N/A
9/30/2018
360
36
N/A
38
N/A
6/30/2018
352
36
N/A
39
N/A
3/31/2018
352
36
N/A
40
N/A
12/31/2017
352
35
N/A
41
N/A
9/30/2017
354
32
N/A
41
N/A
6/30/2017
356
29
N/A
40
N/A
3/31/2017
353
28
N/A
42
N/A
12/31/2016
350
28
N/A
43
N/A
9/30/2016
349
27
N/A
46
N/A
6/30/2016
348
25
N/A
49
N/A
3/31/2016
345
25
N/A
44
N/A
12/31/2015
343
24
N/A
39
N/A
9/30/2015
338
26
N/A
N/A
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8JM's forecast earnings growth (3.9% per year) is above the savings rate (1.9%).
Earnings vs Market: 8JM's earnings (3.9% per year) are forecast to grow slower than the German market (16.1% per year).
High Growth Earnings: 8JM's earnings are forecast to grow, but not significantly.
Revenue vs Market: 8JM's revenue (3.3% per year) is forecast to grow slower than the German market (6.6% per year).
High Growth Revenue: 8JM's revenue (3.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 8JM's Return on Equity is forecast to be low in 3 years time (8.7%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/19 03:56
End of Day Share Price
2026/07/17 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vetoquinol SA is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.